Document is current
Any future updates will be listed below
-
Authors
Chen, Kezhong
Kang, Guannan
Zhang, Zhihong
Lizaso, Analyn
Beck, Stephan
Lyskjær, Iben
Chervova, Olga
Li, Bingsi
Shen, Haifeng
Wang, Chenyang
Li, Bing
Zhao, Heng
Li, Xi
Yang, Fan
Kanu, Nnennaya
Wang, Jun
-
Funding
Funding for this research was provided by:
Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences (2021RU002)
CAMS Innovation Fund for Medical Sciences（CIFMS） (2022-I2M-C&T-B-120)
National Natural Science Foundation of China (No.92059203, No.82072566)
Beijing Natural Science Foundation (L222021)
Peking University People's Hospital Research and Development Funds (RZ2022-03)
- License Information
-
More Information
Article History
Received: 8 June 2022
Accepted: 20 June 2023
First Online: 14 July 2023
Declarations
:
: This study was performed according to the Declaration of Helsinki in 1964 and its current amendments. The study protocol was approved by the Medical Ethics Committee of the Peking University People’s Hospital (approval number: 2018PHB077–01). Written informed consent was obtained from every patient before study enrollment.
: Not applicable.
: Z.Z., A.L., B.L., C.W., B.L., and X.L. declare employment and stock/stock option ownership in Burning Rock Biotech. The remaining authors declare no potential conflict of interest.
